Advertisement

ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.

Sponsored by Eli Lilly and Company

Phase Quota
Phase 2

This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTA alone on you and your malignant pleural mesothelioma as well as make ALIMTA available to patients who qualify for treatment.

Study Start Date: Not specified

Estimated Completion Date: Not specified

Specialties: Pulmonology: Lung/Thoracic Oncology Oncology: Lung/Thoracic Oncology,Pharmacology/Therapy Pharmacy: Chemotherapy/Oncology Physician Assistant: Clinical Pharmacology,Hematology/Oncology

Interventions

  • Drug: Cisplatin
  • Drug: Pemetrexed

Inclusion criteria

  • Have a proven diagnosis of malignant mesothelioma in patients not candidates for curative surgery
  • Prior chemotherapy for your disease is allowed
  • Measurable lesion is not required
  • Have a adequate performance status
  • Sign an informed consent form

Exclusion criteria

  • You are excluded from this trial if you have received any investigational agent within 4 week before enrolling in this study
  • You are excluded from this trial if you have received radiation within the previous 2 weeks
  • You are excluded from this trial if you are a candidates for curative surgery

Study Locations And Contact Information

  • For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician, Porto Alegre RS
  • For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician, Sao Paulo
  • , Cairo
  • For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician, Jeddah
  • For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician, Basking Ridge New Jersey
  • For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician, Cairo

Feature this Clinical Trial

Get your trial in front of 1000s of physicians and patients.
Visit ClinicalTrialsLocator.com to find out how you can feature this clinical trial.

Advertisement